• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Gelatin, Soft Capsule Gelatin, Hard Capsule Gelatin, Pharmaceutical Gelatin-Foodmate
Neohesperidin
Advantame
Cleanroom Bench Horizontal Laminar Flow Hood Airflow Clean Bench
Pharma and Food Grade, USP/FCC Neotame Sweetener E961
Trilobatin

Zydus Cadila gets US FDA nod for anti depressant

expressbpdJune 06, 2017

Tag: Zydus Cadila , FDA , anti depressant

Zydus Cadila has received the US health regulator’s nod to market Mirtazapine orally disintegrating tablets, an anti depressant, in the US market.

Zydus Cadila has received final approval from the US Food and Drug Administration (US FDA) to market the Mirtazapine orally disintegrating tablets USP in strengths 15mg, 30mg and 45mg, the company said in a BSE filing.

The company will manufacture the product at its facility in Baddi.

The Gujarat-based group has more than 115 approvals and has filed over 300 abbreviated new drug applications (ANDAs) since it commenced filings in 2003-04.

Previous:Protalix Wins FDA Approval as Multi-Product Facility

Next:Biocon appoints Pratima Rao as Mission Director of Biocon Foundation

Related News

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

Manulife Hong Kong Partners with New Frontier Group to Enhance Cross-Border Healthcare Services

PRNewswireDecember 12, 2024

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer

PRNewswireDecember 12, 2024

Zydus Cadila gets US FDA nod for anti depressant | Pharmasources.com

Core8 Group and MedArmor to Pioneer Vietnam's First AI x ESG Hospital

PRNewswireDecember 12, 2024

Core8 Group, an Australian leader in high-tech and biotech innovation, has unveiled plans to develop Vietnam's first AI x ESG Hospital, marking a significant milestone in healthcare transformation.

You may like
More>>

Semaglutide(FDA)

Semaglutide(FDA)
Clozapine (FDA)

Clozapine (FDA)
Eptifibatide acetate USFDA china manufacture 99%min

Eptifibatide acetate USFDA china manufacture 99%min
Bleomycin sulfate (FDA)

Bleomycin sulfate (FDA)
Naproxen/ Sodium salt (FDA/COS)

Naproxen/ Sodium salt (FDA/COS)
Ifosfamide (FDA)

Ifosfamide (FDA)
filter integrity testing fda guidelines

filter integrity testing fda guidelines
Tobramycin base( FDA)

Tobramycin base( FDA)
Vinorelbine tartrate (FDA)

Vinorelbine tartrate (FDA)
High quality Stability Chamber(FS/CFS Series:FDA)

High quality Stability Chamber(FS/CFS Series:FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service